



EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Joint Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME TO THE ICPERMED & EP PERMED CONFERENCE





EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME AND OPENING

Gianni D'Errico

Fondazione Toscana Life Sciences & EP PerMed Work Package 5 Lead

Chairman





EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME AND OPENING

Étienne Richer

Genome Canada and ICPerMed Chair



The International Consortium for Personalised Medicine

ICPerMed

Étienne Richer, PhD

ICPerMed-Chair

Genome Canada Director, Genomics Program

ICPerMed and EP PerMed Joint Conference

November 26th 2025





EP PerMed
European Partnership
for Personalised Medicine


ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed – An International Consortium

ICPerMed is a platform that supports strategic coordination, sharing and collaboration to promote research and implementation of personalized medicine (PM) approaches

- 51 European and international partners and growing
- Members include public and private “not-for-profit” health research funding and policy organisations



- **Launched in 2016**

Overall vision:

Research as driver of personalised medicine

The ICPerMed journey – an International Consortium

European Partnership
for Personalised Medicine
Consortium

7th Framework
Programme

Horizon 2020 Framework Programme (H2020)

Horizon Europe Framework Programme

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023





CSA PerMed

ICPerMed

CSA ICPerMed Secretariat

CSA ICPerMed Secretariat

EP PerMed WP5



- Internal and external networking
- Strategic publications
- Communications
- Conferences and Workshops
- Database and information tools



EP PerMed
European Partnership
for Personalised Medicine

A Legacy of Collaborative Leadership

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed
INTERNATIONAL CONSORTIUM

7th Framework
Programme

Horizon 2020 Framework Programme (H2020)

Horizon Europe Framework Programme

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

CSA PerMed

ICPerMed

CSA ICPerMed Secretariat

CSA ICPerMed Secretariat

EP PerMed WP5



Mairéad O'Driscoll



Jan-Ingvar Jönsson




Ejner Moltzen



Étienne Richer

“family” and other supporting initiatives



Since FP7 and during Horizon 2020, the EC provided a budget of more than 2 billion Euros into PM



EP PerMed
European Partnership
for Personalised Medicine

ICPerMed and EP PerMed



ICPerMed
INTERNATIONAL CONSORTIUM



EP PerMed
European Partnership
for Personalised Medicine

With the establishment of the European Partnership for Personalised Medicine (EP PerMed), ICPerMed is now entering a new phase of development in which both organisations will work in close collaboration.

- Through its WP5, EP PerMed supports ICPerMed (eg., funding, organization of meetings and events, social media and website etc...)
- EP PerMed focuses on research funding, innovation building and implementation facilitating
- ICPerMed provides policy and strategic perspectives as well as networking with international partners

New Governance, New Working Groups



Chair

Étienne Richer
CIHR Institute of Genetics
etienne.richer@cihr-irsc.gc.ca



Vice-Chair

Raili Sillart
Estonian Ministry of Social
Affairs
raili.sillart@sm.ee



Vice-Chair


Rizwana Mia
South African Medical
Research Council
rizwana.mia@mrc.ac.za

WG Policy and Strategy
Think tank on the future

Astrid Vicente, INSA, Portugal

WG Internationalisation
Learning and Networking
Globally

Monika Frenzel, ANR, France



**Welcome new
members!**



EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed
INTERNATIONAL CONSORTIUM

THANK YOU!



www.icpermed.eu



EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME AND OPENING

Ondřej Slabý

Czech Health Research Council





EP PerMed
European Partnership
for Personalised Medicine

ICPerMed
INTERNATIONAL CONSORTIUM

**WELCOME TO
PRAGUE!**

ONDŘEJ SLABÝ



AZV  **ČR** CZECH HEALTH
RESEARCH COUNCIL

1st ICPerMed & EP PerMed Joint Conference, November, 2025



PRAGUE – CITY OF A HUNDRED SPIRES



- A city of a thousand stories – of Kafka's introspection, (Švejk's humor), and Havel's courage



- A city of history, culture, and intellectual legacy
- For centuries, a meeting point of Czechs, Germans, and Jews
- A city where freedom of thought and imagination shape the future

PRAGUE – THE SYMBOL OF CONTINUITY



- In Prague, modern science grows beneath ancient towers
- The same spirit that inspired Kepler, Tycho de Brahe, and Dvořák inspires today's research



- Progress is strongest when it honors its roots

CZECH SCIENTIFIC HERITAGE AND BIOMEDICAL EXCELLENCE

- Built on a deep scientific tradition – from Purkyně, Mendel, Wichterle and Holý to today's innovators
- Bridging science and clinical care as the foundation of Czech personalised medicine



CZECH HEALTH RESEARCH COUNCIL AND EUROPEAN PARTNERSHIPS

- The Czech Health Research Council is deeply committed to advancing personalised medicine in Czech Republic and EU.
- Through participation in seven major European partnerships in Healthcare, including EP PerMed, we have already launched nine international calls, two of which directly support the agenda of personalised medicine under EP PerMed.



WELCOME TO PRAGUE

On behalf of Czech Health Research Council and Czech Ministry of Health:

- Welcome to the 1st ICPeMed & EP PerMed Joint Conference in Prague
- May these days bring new ideas, collaborations, and friendships

Welcome to Prague – Vítejte v Praze!



EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME AND OPENING

Pavel Doleček

Technology Agency of the Czech Republic



EU partnerships and Technology Agency

ICPerMed & EP PerMed Joint Conference
26th November 2025, Prague

Pavel Doleček





Why shall we participate in EU partnerships?

- Partnerships and missions represent up to 50% of the budget of HE pillar II
- Topics under partnerships are not anywhere else under HE
- Not being involved = not giving the opportunity to CZ researchers to cooperate on the partnerships topics under HE
- Involvement of a financing organisation (RFO) is the basic condition

Involvement in the EU partnerships = giving chance to Czech entities to participate in international research



Benefits for the country and the RFO

- Coordination and cooperation with other national/regional research funding organisations (sharing of experience)
- Cost savings - joint evaluation covered by the consortium, top up contribution going back to RFO
- Project selection by international experts
- Helping Czech researchers go international = increasing participation in EU programmes (leverage effect)
- Building of international expertise - leadership of WG, tasks, participation in executive board, etc.
- Opportunities to address key strategic challenges of the transnational R&I environment (i.e. through executive bodies, etc.)

Participating states (ministries, research funding organisations) learn from each other, cooperate on the design of topics, make better use of financial resources



Benefits for the beneficiaries

- Involvement in international cooperation
- Funding body is the national research funding organisation - contact person in their language
- Rules according to the national programme - important for submission but also implementation
- Leverage effect - one project leads to others
- International aftercare/additional support services (workshops, networking, etc.)

For many beneficiaries, participation in a call under a partnership is a gateway to international cooperation

Multilateral cooperation: ERA-NET COFUND & Partnerships and others

ERA-NET Cofund + Partnerships



ERA-MIN 3



BiodivRestore



Water4All



EnerDigit



CHIST-ERA IV



**Driving Urban
Transitions (DUT)**



M.ERA-NET 3




QuantERA II



**Clean Energy
Transition (CET)**



BiodivClim



**Innovative
SMEs**



**Partnership for
Biodiversity**

New/continuing schemes of multilateral cooperation of the ERA-NET COFUND & Partnerships type and others

CSA, RIA + Partnerships



LUKE



CHIST-ERA V



**Raw Materials for
the Green and
Digital Transition**



M.ERA-NET 4



QuantERA III



**Forests and
Forestry for a
Sustainable Future**



EP PerMed
European Partnership
for **Personalised Medicine**

ICPerMed
INTERNATIONAL CONSORTIUM

ICPerMed & EP PerMed Conference on Personalised Medicine Research
Day 1, 26 November 2025

WELCOME AND OPENING

Alexandru Costescu

European Commission DG Research & Innovation



Personalised Medicine, from promise to results. Policy update.



Alexandru COSTESCU

Policy Officer, Health Innovations and Ecosystems

DG Research and Innovation, European Commission

Personalised Medicine contributes to:

- foster advancements in fields such as genomics, proteomics, and bioinformatics, thus contributing to our understanding of complex diseases
- develop treatment plans specifically tailored to an individual's genetic makeup, lifestyle, and environment
- reduce ineffective therapies and adverse reactions
- identify early those individuals at risk for certain conditions, enabling preventive measures and timely interventions
- help healthcare systems become better focused while also enhancing patient satisfaction
- contain healthcare costs through improved cost efficiency and optimised use of limited resources and capacities
- expand cross-border collaboration which in turn accelerates innovation and data sharing

Enhanced efforts are needed in several areas:

- a regulatory framework that is better adapted to address the dynamic developments in the personalised medicine area
- develop infrastructure, accreditation and quality control systems, clinical workflows
- resource allocation, specialized trainings, education of the public and equitable access
- find the good balance between citizens' control over their data and enabling advances in research and personalised care
- foster new business opportunities for drug development and health technologies
- guarantee the independence of data-based healthcare in a competitive environment that seeks to transform it into a new commodity
- develop policies that support investment in and uptake of personalized medicine

The Commission's 2024-2029 priorities

A strong emphasis on sustainable competitiveness

A new plan for Europe's sustainable prosperity and competitiveness

Europe as a continent of economic growth, enterprise and innovation by ensuring competitiveness, prosperity and fairness.

**Sustaining our quality of life:
Food security, water and nature**

**Protecting our democracy,
upholding our values**

**Supporting people,
strengthening our societies and
our social model**

**Delivering together and
preparing our Union for the
future**

**A global Europe: Leveraging our
power and partnerships**

**A new era for European Defence
and Security**



The sustainable competitiveness opportunity of Personalised Medicine

The Opportunity for Personalised Medicine

Personalised Medicine approaches have the **potential to increase the sustainable competitiveness** of the European health sector

Personalized medicine within the context of the Sustainable competitiveness Compass.

Innovation – Personalised medicine can revolutionise healthcare through prevention, early detection, precise therapies, and reduced side effects; specially in oncology, rare diseases, and chronic conditions.

Security and resilience – More targeted personalized medicine treatments can increase the efficiency of health care systems and their resilience

Environment – Personalised medicine reduces ineffective treatments, prevents resource waste, and lowers healthcare's environmental impact through targeted prevention and care.



A Strategy for European Life Sciences





Thank you!

#HorizonEU

<http://ec.europa.eu/horizon-europe>



© European Union 2021

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.
Image credits: © ivector #249868181, #251163013, #273480523, #241215668, #245719946, #251163053, #252508849, #241215668, #244690530, #222596698, #235536634, #263530636, #66009682, #273480523, #362422833; © petovarga #366009967; © shooarts # 121467308, 2020. Source: Stock.Adobe.com. Icons © Flaticon – all rights reserved.